(NVST) Envista Holdings - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 3.779m USD | Total Return: 38.9% in 12m
Avg Turnover: 79.0M
EPS Trend: -56.1%
Qual. Beats: 0
Rev. Trend: 54.2%
Qual. Beats: 5
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Envista Holdings Corporation (NYSE: NVST) is a global manufacturer and distributor of dental products, operating through two primary segments: Specialty Products & Technologies and Equipment & Consumables. The company’s portfolio includes dental implants, orthodontic systems, clear aligners, and digital imaging software, marketed under brands such as Nobel Biocare, Ormco, and Dexis. Headquartered in Brea, California, the firm serves a diverse customer base ranging from general dentists to specialized oral surgeons and hospitals.
The dental equipment sector is characterized by a high degree of brand loyalty and significant switching costs, as practitioners often standardize their workflows around specific imaging software and clinical tools. Envista’s business model relies on a mix of high-margin specialized consumables and capital equipment, benefiting from the long-term growth in global demand for aesthetic dentistry and advanced restorative procedures.
Consulting ValueRay can provide further clarity on how these segments influence the companys valuation.
- China volume-based procurement policies pressure dental implant margins and revenue
- Spark clear aligner adoption drives specialty segment growth and market share
- High interest rates reduce consumer demand for elective dental procedures
- Operational restructuring and lean initiatives impact long-term EBITDA margin expansion
- Dental equipment sales sensitivity to high capital expenditure costs for clinics
| Net Income: 67.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.95 > 1.0 |
| NWC/Revenue: 40.33% < 20% (prev 39.00%; Δ 1.33% < -1%) |
| CFO/TA 0.05 > 3% & CFO 272.1m > Net Income 67.7m |
| Net Debt (656.5m) to EBITDA (406.6m): 1.61 < 3 |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (166.4m) vs 12m ago -4.15% < -2% |
| Gross Margin: 55.14% > 18% (prev 0.54%; Δ 5.46k% > 0.5%) |
| Asset Turnover: 50.85% > 50% (prev 45.81%; Δ 5.05% > 0%) |
| Interest Coverage Ratio: 7.32 > 6 (EBITDA TTM 406.6m / Interest Expense TTM 34.7m) |
| A: 0.20 (Total Current Assets 1.92b - Total Current Liabilities 786.6m) / Total Assets 5.58b |
| B: -0.07 (Retained Earnings -401.7m / Total Assets 5.58b) |
| C: 0.05 (EBIT TTM 253.9m / Avg Total Assets 5.52b) |
| D: -0.22 (Book Value of Equity -543.0m / Total Liabilities 2.50b) |
| Altman-Z'' = 1.18 = BB |
| DSRI: 0.99 (Receivables 436.6m/393.1m, Revenue 2.81b/2.50b) |
| GMI: 0.98 (GM 55.14% / 54.18%) |
| AQI: 0.99 (AQ_t 0.58 / AQ_t-1 0.59) |
| SGI: 1.12 (Revenue 2.81b / 2.50b) |
| TATA: -0.04 (NI 67.7m - CFO 272.1m) / TA 5.58b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 23.63 with a total of 2,872,053 shares traded.
Over the past week, the price has changed by +0.90%,
over one month by -13.67%,
over three months by -19.15% and
over the past year by +38.89%.
Envista Holdings has received a consensus analysts rating of 3.29. Therefore, it is recommended to hold NVST.
- StrongBuy: 3
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 29.9 | 26.3% |
P/E Forward = 20.3252
P/S = 1.3456
P/B = 1.2809
Revenue TTM = 2.81b USD
EBIT TTM = 253.9m USD
EBITDA TTM = 406.6m USD
Long Term Debt = 1.44b USD (from longTermDebt, last quarter)
Short Term Debt = 38.7m USD (from shortTermDebt, last quarter)
Debt = 1.74b USD (from shortLongTermDebtTotal, last quarter) + Leases 150.1m
Net Debt = 656.5m USD (calculated: Debt 1.74b - CCE 1.08b)
Enterprise Value = 4.44b USD (3.78b + Debt 1.74b - CCE 1.08b)
Interest Coverage Ratio = 7.32 (Ebit TTM 253.9m / Interest Expense TTM 34.7m)
EV/FCF = 20.14x (Enterprise Value 4.44b / FCF TTM 220.2m)
FCF Yield = 4.97% (FCF TTM 220.2m / Enterprise Value 4.44b)
FCF Margin = 7.84% (FCF TTM 220.2m / Revenue TTM 2.81b)
Net Margin = 2.41% (Net Income TTM 67.7m / Revenue TTM 2.81b)
Gross Margin = 55.14% ((Revenue TTM 2.81b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 55.29% (prev 55.04%)
Tobins Q-Ratio = 0.80 (Enterprise Value 4.44b / Total Assets 5.58b)
Interest Expense / Debt = 2.00% (Interest Expense 34.7m / Debt 1.74b)
Taxrate = 25.86% (13.5m / 52.2m)
NOPAT = 188.2m (EBIT 253.9m * (1 - 25.86%))
Current Ratio = 2.44 (Total Current Assets 1.92b / Total Current Liabilities 786.6m)
Debt / Equity = 0.56 (Debt 1.74b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = 1.61 (Net Debt 656.5m / EBITDA 406.6m)
Debt / FCF = 2.98 (Net Debt 656.5m / FCF TTM 220.2m)
Total Stockholder Equity = 3.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.23% (Net Income 67.7m / Total Assets 5.58b)
RoE = 1.93% (Net Income TTM 67.7m / Total Stockholder Equity 3.50b)
RoCE = 5.14% (EBIT 253.9m / Capital Employed (Equity 3.50b + L.T.Debt 1.44b))
RoIC = 5.02% (NOPAT 188.2m / Invested Capital 3.75b)
WACC = 8.72% (E(3.78b)/V(5.52b) * Re(12.06%) + D(1.74b)/V(5.52b) * Rd(2.00%) * (1-Tc(0.26)))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -1.38%
[DCF] Terminal Value 71.70% ; FCFF base≈239.2m ; Y1≈209.8m ; Y5≈169.5m
[DCF] Fair Price = 11.71 (EV 2.56b - Net Debt 656.5m = Equity 1.91b / Shares 162.7m; r=8.72% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -56.08 | EPS CAGR: -21.06% | SUE: 0.63 | # QB: 0
Revenue Correlation: 54.22 | Revenue CAGR: 2.11% | SUE: 0.91 | # QB: 5
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=+3.79% | Revisions=+29% | Analysts=14
EPS next Quarter (2026-09-30): EPS=0.34 | Chg30d=-5.12% | Revisions=-71% | Analysts=14
EPS current Year (2026-12-31): EPS=1.43 | Chg30d=+1.36% | Revisions=+71% | GrowthEPS=+20.1% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=1.57 | Chg30d=+0.65% | Revisions=+20% | GrowthEPS=+9.8% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: -71%